{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:35:43Z","timestamp":1781217343407,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund (FWF)","doi-asserted-by":"crossref","award":["FWF-P27701-B20"],"award-info":[{"award-number":["FWF-P27701-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003042","name":"Else-Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["P2013_A149"],"award-info":[{"award-number":["P2013_A149"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003494","name":"Herzfelder'sche Familienstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003494","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Austrian Science Fund","award":["SFB F28"],"award-info":[{"award-number":["SFB F28"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.trim.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T23:43:12Z","timestamp":1434238992000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of the mTOR inhibitor everolimus and the PI3K\/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models"],"prefix":"10.1016","volume":"33","author":[{"given":"Sevdican","family":"\u00dcst\u00fcn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lassnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Preitschopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hengstschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weichhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2015.06.001_bb0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1042\/BST20130041","article-title":"A growing role for mTOR in promoting anabolic metabolism","volume":"41","author":"Howell","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.trim.2015.06.001_bb0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.trim.2015.06.001_bb0015","first-page":"3504","article-title":"A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells","volume":"60","author":"Sekulic","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.trim.2015.06.001_bb0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ni0403-313","article-title":"The role of PI3K in immune cells","volume":"4","author":"Koyasu","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","article-title":"Rapamycin: something old, something new, sometimes borrowed and now renewed","volume":"82","author":"Hartford","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.trim.2015.06.001_bb0035","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.trim.2015.06.001_bb0040","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1600-6143.2005.00931.x","article-title":"Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials","volume":"5","author":"Mulay","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.06.001_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","article-title":"Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes","volume":"31","author":"Shihab","year":"2014","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0055","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trim.2015.06.001_bb0065","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200007203430317","article-title":"Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients","volume":"343","author":"Morelon","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2015.06.001_bb0080","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"Saemann","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.06.001_bb0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2014.888056","article-title":"Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms","volume":"13","author":"Duran","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.trim.2015.06.001_bb0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2015.06.001_bb0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","article-title":"Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients","volume":"144","author":"Champion","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0105","first-page":"463","article-title":"Diagnosis of asbestos-related pleuropolmonary diseases","volume":"97","author":"Governa","year":"2006","journal-title":"Med. Lav."},{"key":"10.1016\/j.trim.2015.06.001_bb0110","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2169\/internalmedicine.50.5557","article-title":"Chemical pneumonitis and acute lung injury caused by inhalation of nickel fumes","volume":"50","author":"Kunimasa","year":"2011","journal-title":"Intern. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.anndiagpath.2008.10.001","article-title":"Smoking-related interstitial lung disease","volume":"12","author":"Rao","year":"2008","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.trim.2015.06.001_bb0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1513\/pats.200508-090JS","article-title":"Innate immunity in the lungs","volume":"2","author":"Martin","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.trim.2015.06.001_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1513\/pats.200504-031AC","article-title":"Apoptosis and epithelial injury in the lungs","volume":"2","author":"Martin","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.trim.2015.06.001_bb0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","article-title":"Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury","volume":"133","author":"Imai","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.trim.2015.06.001_bb0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1586\/ers.10.71","article-title":"The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine","volume":"4","author":"Chen","year":"2010","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2613.2007.00566.x","article-title":"Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury","volume":"88","author":"Togbe","year":"2007","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.trim.2015.06.001_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-430-8_1","article-title":"Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life","volume":"821","author":"Weichhart","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trim.2015.06.001_bb0150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1042\/BST20130032","article-title":"Immune responses of macrophages and dendritic cells regulated by mTOR signalling","volume":"41","author":"Katholnig","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.trim.2015.06.001_bb0155","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.4049\/jimmunol.1000296","article-title":"A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation","volume":"185","author":"Haidinger","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2008-02-137430","article-title":"Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells","volume":"112","author":"Ohtani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trim.2015.06.001_bb0165","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.trim.2015.06.001_bb0170","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.4049\/jimmunol.1200069","article-title":"Cutting edge: mTORC1 in intestinal CD11c+CD11b+ dendritic cells regulates intestinal homeostasis by promoting IL-10 production","volume":"188","author":"Ohtani","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0175","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.4049\/jimmunol.1102187","article-title":"The role of tuberous sclerosis complex 1 in regulating innate immunity","volume":"188","author":"Pan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0180","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-10-3968","article-title":"mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment","volume":"71","author":"Jiang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.trim.2015.06.001_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nm.2157","article-title":"Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema","volume":"16","author":"Yoshida","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2015.06.001_bb0190","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1003655","article-title":"Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis","volume":"188","author":"Fielhaber","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2015.06.001_bb0235","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.ajpath.2014.06.002","article-title":"Rtp801 suppression of epithelial mTORC1 augments endotoxin-induced lung inflammation","volume":"184","author":"Nadon","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trim.2015.06.001_bb0200","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trim.2015.06.001_bb0205","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trim.2015.06.001_bb0210","doi-asserted-by":"crossref","first-page":"L379","DOI":"10.1152\/ajplung.00010.2008","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.trim.2015.06.001_bb0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1165\/rcmb.2008-0290OC","article-title":"Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury","volume":"41","author":"Lorne","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.trim.2015.06.001_bb0240","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1165\/rcmb.2013-0171OC","article-title":"T cells and lung injury: impact of rapamycin","volume":"51","author":"Nakajima","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.trim.2015.06.001_bb0225","first-page":"3112","article-title":"Inactivation of mammalian target of rapamycin (mTOR) by rapamycin in a murine model of lipopolysaccharide-induced acute lung injury","volume":"124","author":"Wang","year":"2011","journal-title":"Chin. Med. J."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327415300046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327415300046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T12:07:12Z","timestamp":1691755632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327415300046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0966327415300046"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2015.06.001","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the mTOR inhibitor everolimus and the PI3K\/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}